Role of the Microbiome in Interstitial Lung Diseases

• Published in: Frontiers in medicine Vol. 8; p. 595522
• Main Authors: Chioma, Ozioma S, Hesse, Laura E, Chapman, Austin, Drake, Wonder P
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 28.01.2021
• Subjects: fibrosis; gut microbiome; idiopathic pulmonary fibrosis; infection; interstitial lung disease (ILD); Medicine; sarcoidosis; infection; gut microbiome; lung microbiome; interstitial lung disease (ILD); fibrosis; sarcoidosis; idiopathic pulmonary fibrosis
• ISSN: 2296-858X; 2296-858X
• DOI: 10.3389/fmed.2021.595522

There are trillions of microorganisms in the human body, consisting of bacteria, viruses, fungi, and archaea; these collectively make up the microbiome. Recent studies suggest that the microbiome may serve as a biomarker for disease, a therapeutic target, or provide an explanation for pathophysiology in lung diseases. Studies describing the impact of the microorganisms found in the respiratory tract on lung health have been published and are discussed here in the context of interstitial lung diseases. Additionally, epidemiological and experimental evidence highlights the importance of cross-talk between the gut microbiota and the lungs, called the gut-lung axis. The gut-lung axis postulates that alterations in gut microbial communities may have a profound effect on lung disease. Dysbiosis in the microbial community of the gut is linked with changes in immune responses, homeostasis in the airways, and inflammatory conditions in the gastrointestinal tract itself. In this review, we summarize studies describing the role of the microbiome in interstitial lung disease and discuss the implications of these findings on the diagnosis and treatment of these diseases. This paper describes the impact of the microbial communities on the pathogenesis of lung diseases by assessing recent original research and identifying remaining gaps in knowledge.